The excitatory amino acid transporter 2 (EAAT2) is responsible for the majority of glutamate uptake in the brain and its dysregulation has been associated with multiple psychiatric and neurological disorders. However, investigation of this molecule has been complicated by its complex pattern of alternative splicing, including three coding isoforms and multiple 5 0 -and 3 0 -UTRs that may have a regulatory function. It is likely that these sequences permit modulation of EAAT2 expression with spatial, temporal and or activity-dependent specificity; however, few studies have attempted to delineate the function of these sequences. Additionally, there are problems with the use of antibodies to study protein localization, possibly due to posttranslational modification of critical amino acid residues. This review describes what is currently known about the regulation of EAAT2 mRNA and protein isoforms and concludes with a summary of studies showing dysregulation of EAAT2 in psychiatric and neurological disorders. EAAT2 has been either primarily or secondarily implicated in a multitude of neuropsychiatric diseases in addition to the normal physiology of learning and memory. Thus, this molecule represents an intriguing therapeutic target once we improve our understanding of how it is regulated under normal conditions.
Relevance of glutamatergic neurotransmission
Glutamate is the major excitatory neurotransmitter in the central nervous system and plays a key role in neuroplasticity and brain development. As an amino acid, it was not immediately apparent that glutamate had such an important signaling function in the brain. The first suggestion that glutamate was a synaptic neurotransmitter was made in 1954 following the observation that injection of the amino acid caused convulsions, 1 although the mechanism and importance of glutamate uptake in the brain was not recognized until the 1970s. 2 Since then, a family of five high-affinity glutamate transporters has been characterized that is responsible for the precise regulation of glutamate levels at both synaptic and extrasynaptic sites, although the glutamate transporter 1 (GLT1) is responsible for more than 90% of glutamate uptake in the brain. 3 The importance of GLT1 is further highlighted by the large number of neuropsychiatric disorders associated with glutamate-induced neurotoxicity.
Clarification of nomenclature
The major glial glutamate transporter is referred to as GLT1 in the rodent literature and excitatory amino acid transporter 2 (EAAT2) in the human literature. Therefore, we use EAAT2 to describe studies that were performed using human tissue and GLT1 to describe studies involving rodents. In addition, multiple isoforms of GLT1 have been identified; however, naming of these isoforms has been inconsistent. Therefore, we refer to the originally cloned isoform as GLT1, whereas other investigators have referred to this splice form as GLT1a. Out of respect for the individuals who initially cloned these molecules, we have chosen not to use the term GLT1a, although we acknowledge that it may be a useful designation for identifying studies that distinguished between the isoforms. Some groups have referred to GLT1b as GLT1v, but we use the term GLT1b in this review for consistency.
Overview of the high-affinity glutamate transporters GLT1 was cloned by screening a rat brain cDNA library with an antibody raised against the purified transporter. 4 A probe designed from the cloned sequence detected an 11 kb fragment on a northern blot in the brain but not in peripheral tissues. Remarkably, this was the first observation that the GLT1 transcript was much longer than the cloned sequence. However, it was not until 2003 that the full-length 3 0 -UTR was identified. 5 The predicted protein contains 573 amino acids with eight or possibly more transmembrane domains and has a molecular weight of about 64 kDa. The encoded transporter did not share significant sequence homology with any known eukaryotic protein identified at that time, including the superfamily of neurotransmitter transporters. The human 6 and mouse 7, 8 orthologs were cloned a few years later. The GLT1 transcript is about 11.7 kb, with 10 protein coding exons and a 3 0 -UTR of about 9.5 kb, containing multiple polyadenylation sites.
GLT1 is one of five high-affinity glutamate transporters that are part of the solute carrier 1 family. These molecules transport glutamate together with three Na þ and one H þ , coupled to the countertransport of one K þ ion. 9 By transporting ions down their concentration gradients, glutamate can be moved out of the synapse to maintain low extracellular levels. GLAST (EAAT1) is also found in astrocytes, as well as in heart, skeletal muscle and placenta. 10, 11 EAAC1 (EAAT3) is a neuronal transporter that is abundant in the cerebral cortex, hippocampus, red nucleus, substantia nigra and caudateputamen, and is present in the intestine, kidney, liver and heart. [12] [13] [14] EAAT4 is found predominantly in cerebellar Purkinje cells 15 and EAAT5 is expressed primarily in the retina. 16 These transporters exhibit 44-55% similarity at the amino acid level. 17, 18 Pharmacologically, EAAT2 differs from other members of the family in that it is inhibited by dihydrokainate and kainate, whereas the other transporters are not. 19 In recent years, progress has been made in identifying compounds that selectively inhibit EAAT2 without blocking the other high-affinity glutamate transporters. 20 EAAT2 transports glutamate into astrocytes for conversion into glutamine, which is then released and recycled by neurons to generate glutamate. This process is thought to contribute to energy metabolism in the brain, because if glutamate were not recycled by conversion into glutamine and had to be synthesized repeatedly, glucose consumption in the brain would be much higher. 21 Although diffusion removes some glutamate from synapses, this method alone is not sufficient for maintaining physiological glutamate levels. Initially, researchers thought that the uptake process was too slow to play a major role in regulation of synaptic glutamate. However, current hypotheses involve regulation by rapid binding of glutamate to the transporter to prevent interaction with glutamate receptors. 22 
Alternative splicing of GLT1
Alternate C-termini The GLT1b isoform was first cloned from mouse tissue in 1997, but neither the authors nor other researchers realized the significance of this discovery at the time. Figure 1 shows the alternatively spliced C-termini of the key isoforms. Table 1 lists the unique N-and C-terminal sequence for these variants. The key finding in this study was a liver-specific variant with a unique 5 0 end, with little attention paid to the two C-terminal regions identified in both brain and liver. 23 The first real efforts to characterize GLT1b occurred after two independent groups cloned the transcript from rat neurons. 24, 25 This variant included the N-terminal region of the original isoform cloned by Pines and colleagues with the C-terminus identified previously in liver and brain. The 11 unique amino acids at the C-terminus of GLT1b encode a PDZ-binding domain that may allow this isoform to interact with synaptic scaffolding molecules. The regional expression profiles of the GLT1a and GLT1b proteins are very similar, with high expression in the cortex, hippocampus, striatum, and thalamus and lower expression in the cerebellum, pons, and medulla. 24 The transport properties of the two splice Figure 1 Diagram of glutamate transporter 1 (GLT1) Cterminal splice variants. Exons 10 and 11 are shown and the unique exons of GLT1b and GLT1c are depicted as narrow boxes. Solid lines represent 3 0 -UTR sequence and dashed lines represent intron. The intronic sequence between exons 10 and 11 in GLT1 makes up the 3 0 -UTR of GLT1b. The sequence that makes up exon 11 in GLT1 is part of the 3 0 -UTR of GLT1b and GLT1c. 24, 26 suggesting that any functional difference between the two isoforms likely involves different cellular localization patterns or participation in different signaling pathways.
A third functional GLT1 variant encoding yet another novel C-terminus, referred to as GLT1c, was recently identified in the rat and human retina. 27 This splice form includes exons 1 through 10 and then terminates with a small alternate exon spliced in from intron 10. The novel exon encodes 11 unique amino acids at the C-terminus of the protein with a PDZbinding domain, reminiscent of GLT1b. The protein is abundant in the retina and expressed at very low levels in the brain, primarily in end-feet of astrocytes. GLT1c appears to be the presynaptic photoreceptor glutamate transporter that was thought to exist based on electrophysiological experiments. 28 This variant adds an additional layer of complexity to the story because probes designed to target the GLT1c transcript overlap with at least one 3 0 -UTR isoform of GLT1b. Moreover, there may be additional transcripts encoding unique proteins that have not yet been identified.
Multiple EAAT2 transcripts are generated through the use of alternate polyadenylation sites, creating transcripts of different lengths. 29 Interestingly, regions such as the thalamus, where the shorter transcripts are more abundant than the full-length mRNA, are associated with lower EAAT2 protein levels. The reduced protein levels may occur because the shorter transcripts are less stable or are translated less efficiently, although these possibilities have not been explored in depth.
Regulation of GLT1 expression by functional elements in the 3
0 -UTR The 3 0 -UTR of GLT1 is among the longest reported, suggesting that it contains elements that regulate translation, mRNA localization or mRNA stability. In addition to the terminal coding region (and probably the 5 0 -UTRs), the 3 0 -UTRs of GLT1 and GLT1b contain at least some sequence unique to each isoform. These regions could contain regulatory elements that control the differential expression of the two isoforms. The GLT1c 3 0 -UTR is predicted to be identical to that of GLT1 and thus may not contain any unique 3 0 -UTR sequence, although its complete length is not yet known.
One study determined that regions of the GLT1 3 0 -UTR that are probably unique to GLT1 either increase or decrease expression of a reporter gene in cultured astrocytes. 5 Their results were somewhat different with an immortalized glioma cell line, suggesting that regulation of GLT1 expression by the 3 0 -UTR may be cell type-specific. The extreme 3 0 end of the GLT1 transcript is highly conserved between human and rat, which strongly suggests that this region has a regulatory function. Notably, only this single investigation has been performed to delineate functional sequence elements in the 3 0 -UTR of GLT1. Additional studies of this nature should be performed to identify target regions for putative regulatory molecules.
Taken together, cis-acting regulatory elements in the 3 0 -UTRs of GLT1 and GLT1b (and plausibly unique 5 0 -UTRs) could account for the differences in their regional, cellular and temporal localization patterns. Thus, although GLT1b and GLT1c are expressed at much lower levels than GLT1 in homogenized brain tissue, their expression patterns may be more tightly controlled by trans-acting factors such as RNA-binding proteins.
Post-transcriptional control of gene expression is regulated by functional elements in the 3 0 -UTRs of some genes. 30 Translational repression could also offer a partial explanation for findings of altered protein levels with no change in RNA expression in pathological conditions. The 3 0 -UTR of GLT1 contains predicted K boxes, which serve as binding sites for microRNAs (miRs). 31 Computational predictions indicate that there is a predicted binding site in the distal 3 0 -UTR sequence that is unique to GLT1 for miR-218. 32 This molecule may serve as a specific regulator of GLT1 because the portion of the 3 0 -UTR that contains the binding site is not part of the GLT1b transcript. The miR-182 and miR-200b molecules may also bind to the 3 0 -UTR but in a more proximal region shared by all known GLT1-coding isoforms.
Evidence for an extended GLT1b transcript
The cloned GLT1b transcript includes a complete open reading frame, but is missing much of the 3 0 -UTR. One study included a northern blot with RNA from rat cultured neurons and probes to the 3 0 -UTR regions of GLT1 and GLT1b. Both probes produced a signal at B11 kb and the GLT1b probe also produced a robust band at B3 kb. 24 Another northern blotting experiment, using RNA from rat whole brain, hippocampus and neocortex with probes that recognized GLT1 and GLT1b, identified an 11 kb transcript for GLT1 and a 12.5 kb transcript for GLT1b. 25 However, the authors of these studies did not discuss the longer GLT1b transcript or attempt to account for the additional sequence. We have shown that a northern blot with a probe in the distal portion of intron 10, a region previously believed not to be part of GLT1b, also gives an 11 kb band. 33 One implication of the longer GLT1b transcript is that it contains a large region of highly conserved sequence that is not included in the GLT1 transcript, providing a target for unique regulatory mechanisms. Upstream open reading frames (ORFs), which may be translated or inhibit translation of the main protein product, are present in some of these 5 0 -UTRs. 34, 36 Variants that encode upstream ORFs (such as the molecules annotated as HBGTIIB and HBGTIIC) appear to be less abundant than those that do not encode upstream ORFs. 34 A mouse model of chemically induced hypoxia was used to demonstrate that regulation of GLT1 splice forms with alternative 5 0 ends is specific to certain brain regions. For instance, two 5 0 variants were upregulated in the frontal cortex and downregulated in the hippocampus in this model. 39 To date, no one has established whether any of these alternative 5 0 ends is specific to GLT1 or GLT1b. However, we have generated evidence that the GLT1b 3 0 end may be preferentially associated with the HBGTII/IIC 5 0 end during human development. 40 
Expression of aberrant EAAT2 transcripts
Multiple additional EAAT2 splice forms have been identified, although it is not clear whether any of them are translated into protein. For instance, glioma cells that express aberrant GLT1 mRNA do not appear to express GLT1 protein. 41 These transcripts may be translated into unstable proteins, making them difficult to detect in standard assays, or they may function in some other way to downregulate transcription or translation. If this type of regulation is occurring in vivo, then the abnormal splice forms may serve to maintain a lower expression of EAAT2 protein, and thus promote excitotoxicity.
One study provided evidence that aberrant EAAT2 transcripts, including a variant that retained intron 7 and another that skipped exon 9, were responsible for the decreased EAAT2 protein in amyotrophic lateral sclerosis (ALS) motor cortex and spinal cord. 42 The variant with exon 9 skipped lacks the motif that triggers export of the transporter from the endoplasmic reticulum. 43 Retention of intron 7 introduces premature termination codons that should mark the transcript for nonsense-mediated decay. 44 Thus, it appeared that overexpression of either of these isoforms might explain reduced EAAT2 protein and activity in ALS. However, subsequent studies demonstrated that the intron 7-retained and exon 9-skipped transcripts could also be detected in patients with other neurodegenerative disorders and normal controls. [45] [46] [47] In our own experiments, we have determined that expression of the exon 9-skipped transcript is significantly higher in the primary motor cortex than in other frontal cortical regions, although we did not find a difference in the level of these transcripts between ALS and control tissue. Thus, at least the exon 9-skipped transcript may play a normal physiological role in regulation of EAAT2 levels. It remains puzzling why these transcripts appeared to be specific to ALS patients in the carefully conducted study by Lin and colleagues. 42 However, technologies and statistical corrections to evaluate gene expression have evolved markedly in the last few years and many investigators have used different methods and brain tissues to evaluate EAAT2. Therefore, comparison of data between groups may not always be appropriate. With more sophisticated technology for quantitative reverse transcriptase -PCR, we and others are revisiting the question of quantitative differences in the expression of these transcripts in disease.
Localization of GLT1
GLT1/EAAT2 and GLT1b/EAAT2b are clearly predominantly expressed in astrocytes under normal conditions, 14, 48, 49 although they are also expressed in oligodendrocytes and neurons. 25 Expression of EAAT2 in oligodendrocytes is interesting because decreases in EAAT2 immunoreactivity have been observed in the white matter from patients with active multiple sclerosis (MS) lesions, although it is not clear whether this is a primary or secondary effect of MS pathology. 50 Still, blocking glutamate uptake by GLT1 and GLAST in cultured oligodendrocytes or isolated optic nerve leads to cell death, demyelination and axonal damage, suggesting that GLT1 is important for normal oligodendrocyte function. 51 In contrast, although GLT1 mRNA and protein have been detected in neurons in vitro and in vivo, no one has proven that GLT1 functions as a transporter in neurons. However, it should be noted that elevated expression of GLT1b/EAAT2b in neurons has consistently been correlated with various pathological states in animal models and in human postmortem tissue. Therefore, an important question that remains is whether or not one of the EAAT2 isoforms plays a functional role in a subset of neurons under normal conditions or whether its appearance in neurons is purely a marker of pathology.
Two independent groups cloned the GLT1b isoform and detected the protein in neurons both in cultured cells and in rat brain tissue. 24, 25 As neither group had previously been able to detect the main GLT1 isoform in neurons, as GLT1 immunoreactivity in the retina is confined to neurons, 52 and because GLT1b is the major isoform in the retina, 53 it seemed plausible at the time that GLT1b might be a primarily neuronal variant. However, more recent studies have established that GLT1 is far more abundant than GLT1b in both neurons and astrocytes, indicating that GLT1b is neither unique to neurons, nor is it the predominant isoform in neurons. 54, 55 In retrospect, it is possible that the use of various immunohistochemical techniques, such as employing ultrathin sections and fixation without glutaraldehyde, may have produced the confusing results observed in 2002.
The subcellular localization also appears to be different for the two major isoforms of GLT1. GLT1 is detected primarily in the cell membrane, whereas GLT1b is predominantly cytoplasmic and granular. 25 The granular staining pattern suggests that the protein is found in vesicles. This observation raises a question of how GLT1b contributes to regulation of EAAT2 regulation and splicing TL Lauriat and LA McInnes extracellular glutamate levels. One possibility is that the protein may be localized to the cytoplasm under normal conditions and trafficked to the membrane in an activity-dependent manner. Alternatively, proteins that interact with the C-terminus of GLT1b could prevent the antibody from recognizing the antigen at the membrane. Another study demonstrated that GLT1 was expressed in glial membranes that interdigitated between synapses, whereas GLT1b was excluded from the tips of astrocytes between synapses. 26 These investigators suggested that GLT1b may be important in controlling extrasynaptic glutamate but may not regulate glutamate uptake at the synapse. A subsequent report by an independent group confirmed that GLT1 mRNA is present in astrocyte processes, whereas GLT1b mRNA is found primarily in the cell bodies. 55 Although the reason for the different subcellular localization of these isoforms has not been determined, it is probably due to targeting elements in the C-terminal region of the protein or functional elements in the 3 0 -UTR. It is also possible that splicing and translocation of GLT1 occur in an activity-dependent manner, which could contribute to discrepancies among reported studies.
The fact that GLT1 has been detected at higher levels in astrocytes in the pyramidal cell layer in the hippocampus than in the adjacent molecular layers, while GLT1b shows a more homogeneous distribution, has also been interpreted as evidence of differential regulation. 55 These authors suggested that a factor present in the pyramidal cell layer may influence expression of GLT1 but not GLT1b. One mechanism that might mediate the differential targeting is via the unique C-terminal region of GLT1b, which encodes a PDZ-binding domain that interacts with protein kinase Ca binding protein (PICK1). 56 The interaction between PICK1 and GLT1 should be specific to GLT1b because the binding site is not present in GLT1. Consequently, GLT1 cannot be regulated in the same manner via interactions with the C-terminus of the protein. Similar motifs are also present in GLT1c, GLAST, EAAT4 and EAAT5, suggesting that interactions between glutamate transporters and PDZ proteins may be common. 57 Finally, given the fact that GLT1 isoforms do appear to be expressed in at least a subset of hippocampal neurons, [58] [59] [60] [61] and the evidence for differential regulation, it seems important to address the possibility that one or more GLT1 isoforms could be regulated in an activity-dependent manner. Proving that activitydependent expression of GLT1 plays a functional role in long-term potentiation (LTP) would require the use of electrophysiological paradigms, demonstration that the protein is trafficked to the cell membrane, and evidence for functional glutamate uptake by GLT1 in response to stimulation.
Species heterogeneity in expression
There is extensive heterogeneity in GLT1 expression patterns among species, which has complicated studies of cell type-specific expression. 62 In a study examining rodents, rabbits, cats, pigs, monkeys and humans, GLT1 was abundant in rodent white matter astrocytes but was present only in a small subset of these astrocytes in human and cat. Interestingly, oligodendrocytes appear to be the primary cell population expressing GLT1 in porcine brain. 62, 63 Williams and colleagues were unable to detect GLT1b in rabbit and monkey brain, although their antibody recognized the protein in retina from these species. They also found patches of cortical tissue that were stained by pan-specific GLT1 antibodies but not by antibodies specific to either GLT1 or GLT1b. Their tentative explanation for this observation is that the C-terminus of GLT1b may undergo regulated cleavage, making it unrecognizable by GLT1b antibodies.
Another interesting observation, although its functional purport is not clear, is that a transcript called 'noncoding transcript abundantly expressed in brain' (Ntab) was identified in a study aimed at finding genes that were differentially expressed following the induction of LTP in rat brain. 64 This noncoding RNA molecule was approximately 4 kb, based on a northern blot. The corresponding region in the human sequence was subsequently annotated as part of the 3 0 -UTR of EAAT2. 5 When Ntab was cloned, there were few known transcripts with such long 3 0 -UTRs so that it was not immediately obvious that Ntab, or possibly its antisense, was also part of the GLT1 3 0 -UTR. Moreover, the pattern of expressed sequence tags in the region further supported the possibility that Ntab was an independent molecule downstream of GLT1. We have subsequently demonstrated that a northern blot with a probe to Ntab detects both the full-length GLT1 transcript and a transcript of about 4 kb.
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EAAT2 in neuropsychiatric and neurological disorders
The importance of studying EAAT2 is evidenced by the extensive list of conditions associated with altered glutamate transporter expression in human studies and animal models. The disorders that will be discussed below include amyotrophic lateral sclerosis, schizophrenia, mood and anxiety disorders, Alzheimer's disease, epilepsy, hypoxia, ischemia, Huntington's disease, brain injury, glaucoma, HIVassociated dementia and addiction. Induction of LTP, a molecular correlate of learning and memory, by tetanic stimulation in CA1 is impaired in GLT1 null mice, suggesting that EAAT2 may play a role in normal cognition. 65 Thus, it is not surprising that dysregulation of EAAT2 and other glutamate transporters is associated with several psychiatric and neurological diseases characterized by cognitive impairment. Studies suggesting differential regulation of GLT1 and GLT1b in pathological conditions or in response to experimental manipulations are described in Table 2 .
Amyotrophic lateral sclerosis
The most direct evidence linking EAAT2 with a particular disease exists for ALS. EAAT2 protein expression is decreased substantially in the motor cortex of individuals with ALS, without a corresponding change in the total mRNA level, suggesting that defects in splicing or some other posttranscriptional mechanism may be the cause. 66, 67 Decreased EAAT2 protein has also been demonstrated in the spinal cord and motor cortex by immunohistochemistry. 68 In contrast, EAAT2b protein is increased in ALS motor cortex, but the upregulation of this isoform is not able to compensate for the loss of EAAT2 expression. Notably, increased expression of the molecule occurs primarily in the somatodendritic compartment of pyramidal cells rather than astrocytes where this isoform is found in the normal brain. 69 We have recently shown that a variant of EAAT2 with a short alternative 3 0 -UTR and EAAT2b are actually increased in ALS motor cortex at the transcript level (unpublished observations). It remains to be determined whether an increase in an EAAT2 transcript with a shorter 3 0 -UTR is physiologically meaningful in this condition or whether the transcript is associated with an aberrant splice variant that has not yet been determined. In addition, the HBGTII 5 0 variant is upregulated in ALS motor cortex. Increased expression of this variant is particularly interesting because the 5 0 end encodes an upstream open reading frame, which may function to decrease expression of the main protein product by causing the ribosome to dissociate prematurely. If increased expression of this splice variant in fact leads to decreased production of EAAT2 protein, it could explain why protein levels are decreased while mRNA levels are increased or unchanged in ALS. It is also interesting that this variant and EAAT2b showed similar changes in expression in both the ALS study and in our investigation of EAAT2 across human development.
A likely explanation is that this 5
0 -UTR is unique to the EAAT2b isoform and provides a means for differential regulation. As mentioned previously, others have reported conflicting data regarding the presence of certain 'aberrant' splice variants in ALS tissue, including the exon 9-skipped and intron 7-retained isoforms. However, we have found no difference in either of these two transcripts in motor cortex or lumbosacral spinal cord from subjects with ALS versus controls using isoform-specific probes.
Both animal and cell culture models have been used to demonstrate the role of EAAT2 downregulation in the pathogenesis of ALS. A mouse model of the Guamian ALS-Parkinsonism dementia complex showed decreased GLT1 protein in the spinal cord and somatosensory cortex and decreased GLT1b protein in these regions as well as in the striatum, motor cortex and piriform cortex. 70 As GLT1b expression was decreased in regions where GLT1 was unaffected, the results provide evidence of differential regulation of these isoforms. Neuropathological studies of double transgenic mice expressing the superoxide dismutase (SOD) mutation associated with ALS, and also overexpressing GLT1, showed some delay in the death of spinal motor neurons and a delay in the decline of grip strength. 71 However, the double transgenic mice did not live longer and the onset of paralysis was not delayed, suggesting that decreased GLT1 may contribute to motor neuron death in ALS, but is not the cause of the motor neuron degeneration. Consistent with this hypothesis, SOD mutant mice that are heterozygous for a null allele of GLT1 show an accelerated decline in motor function and earlier loss of motor neurons than mice with the SOD mutation and normal levels of GLT1. 72 One study established that 5 0 splicing of GLT1 is altered in the spinal cord of SOD transgenic mice, indicating a possible link between altered splicing patterns and ALS. 36 73 Likewise, other investigators have reported decreased expression of EAAT2 in the dorsolateral prefrontal cortex of subjects with SCZ, although most of the changes were only at a trend level. 74 This group also found decreased expression in the parahippocampal region, with no change in other hippocampal regions. 75 These investigators posited that even subtle changes in the ratio of metabotropic glutamate receptors to EAAT2 in subjects with SCZ might have a biological effect on glutamatergic signaling. 74, 76 Moreover, another group has shown that subjects with the high-risk metabotropic glutamate receptor 3 (GRM3/mGluR3) haplotype associated with SCZ had lower EAAT2 expression in the prefrontal cortex. 77 In the striatum, there does not appear to be a difference in EAAT2 expression between subjects with SCZ and controls. 78 However, there is evidence that expression of EAAT3 and EAAT4, the neuronal transporters, are differentially expressed between schizophrenics and controls in this tissue. It is possible that expression of EAAT2 mRNA in neurons may be altered but this has not been detected because most of the expression is in astrocytes.
One caveat of postmortem tissue studies of SCZ is that it is difficult to control for the effects of exposure to antipsychotic medications. To address this issue, several groups have examined GLT1 expression in rodents treated with these drugs. Rats that received 25-35 mg/kg per day of oral clozapine expressed less GLT1 than controls, resulting in decreased glutamate transport and increased extracellular glutamate levels after three weeks. 79 In another study, rats that received 45 mg/kg per day of oral clozapine for six months exhibited decreased GLT1 expression in CA1 of the hippocampus and the parietal, frontal, cingulate, and temporal regions of the cortex. 80 In the same study, rats that received 1.5 mg/kg per day of haloperidol for six months had decreased GLT1 expression in the frontal and cingulate cortex. A similar finding was reported in the striatum after 30 days of treatment with 0.5 mg/kg per day of haloperidol or 10 mg/kg per day of clozapine administered intraperitoneally. 81 A more recent study used cultured astrocytes to show that downregulation of GLT1 by clozapine occurs primarily in astrocytes. 82 Thus, the rodent literature suggests that exposure to antipsychotics affects GLT1 expression.
Mood and anxiety disorders
There is evidence from animal models that GLT1 expression is regulated both by stress and by drugs that are used as therapeutic agents for mood and anxiety disorders. Chronic restraint stress in rats modulates GLT1 and GLT1b independently of one another. Specifically, chronic restraint stress was associated with an increase in GLT1 mRNA and protein levels in the CA3 region of the hippocampus that was reversible by administration of the antidepressant tianeptine. 83 In contrast, GLT1b was regulated only at the protein level in several hippocampal subfields and the effects were not altered by tianeptine. GLT1 expression is also regulated by glucocorticoids including corticosterone and the synthetic molecule dexamethasone. 38, 84, 85 Corticosterone was found to regulate translation of GLT1 isoforms with longer 5 0 -UTRs, but not to affect transcription or protein stability. 38 This molecule led to a dosedependent increase in GLT1 protein levels in cultured astrocytes, further supporting the notion that isoforms of GLT1 are differentially regulated in response to stress.
Another study demonstrated that the increase in GLT1 expression caused by chronic stress was blocked by administration of lithium. 86 Earlier work in brain slices demonstrated that lithium caused an increase in glutamate accumulation through inhibition of glutamate uptake. 87 Notably, lithium affects the conformational state of the transporter and may be transported through one of the sodium sites. 88 In addition, modulation of GLT1 expression is mediated by pathways involving phophatidylinositol 3-kinase (PI-3K), which is also modulated by lithium. 89 A recent study using lentiviral vectors expressing dominant-negative and constitutively active AKT1 in cultured astrocytes demonstrated that AKT1 regulates GLT1 mRNA and protein expression in astrocytes. 90 It is interesting to postulate that lithium may exert its therapeutic actions through modulation of GLT1, which in turn could affect the AKT/PI-3K pathway.
One gene expression microarray study identified EAAT2 as downregulated in the dorsolateral prefrontal cortex and anterior cingulate cortex of individuals with major depression. 91 This study included nine subjects with major depression, six with bipolar disorder, and seven normal controls. Unlike studies of schizophrenia, this one was not confounded by exposure to antipsychotic drugs. No other studies have specifically examined EAAT2 expression in major depression or bipolar disorder.
Protein kinase C (PKC) has varying effects on GLT1 expression and activity in different cell lines. The relationship between PKC and GLT1 is particularly interesting, given that bipolar disorder is associated with abnormalities of PKC signaling. 92 In primary neuron-astrocyte co-cultures, activation of PKC with phorbol esters led to a decrease in GLT1 protein at the cell surface without altering total GLT1 protein content. 93 This decrease in membrane expression was accompanied by a decrease in transport activity mediated by GLT1. Similarly, decreased translocation of PKC to the membrane has been demonstrated in rat brain slices and cell culture models following administration of lithium. 92 More recent studies have
shown that PKC-a interacts with GLT1 to regulate its activity and possibly trafficking of GLT1 to the membrane. 93, 94 In addition, brain derived neurotrophic factor (BDNF), a molecule that has been consistently implicated in mood disorders, causes upregulation of GLT1 expression in differentiated astrocytes that is accompanied by increased glutamate uptake. 95 This effect appears to be specific to BDNF and GLT1, as other neurotrophic factors did not influence GLT1 expression and BDNF had no effect on expression of the other glial glutamate transporter, GLAST.
Alzheimer's disease Some neurons containing neurofibrillary tangles and abnormal tau protein from subjects with AD express EAAT2 protein, suggesting the possibility that neuronal expression is associated with pathological states. The notion of aberrant neuronal expression of EAAT2 in disease states is a recurring theme that has been observed in multiple studies. Populations of neurons that were immunoreactive included cortical pyramidal cells, dentate granule cells, neurons in the substantia nigra and locus coeruleus, and neurons in the paraventricular nucleus of the hypothalamus. 96 In another study, a 50% decrease in EAAT2b immunoreactivity was observed in motor cortex of AD patients, although only five subjects were included in this study. 69 One study found decreased EAAT2 immunoreactivity and glutamate transporter activity in the frontal cortex of AD patients without a corresponding change in the mRNA level. 97 Likewise, transgenic mice that overexpress mutant amyloid precursor protein (APP) exhibit reduced expression of GLT1 protein with no change in mRNA levels. 98 These findings again implicate defective splicing or posttranscriptional processing of EAAT2 in disease processes such as AD. In addition, treating cultured astrocytes with a low dose of b-amyloid, which makes up the plaques found in AD brains, led to enhanced translation of EAAT2 mRNA. 38 Another group found that low concentrations of b-amyloid increased EAAT2 expression through a pathway involving the transcription factor NF-kB. 95 Thus, b-amyloid appears to influence EAAT2 expression at both the transcriptional and translational levels.
Epilepsy
High extracellular glutamate levels lead to excitotoxicity, a state that may be associated with epilepsy. As EAAT2 expression is very high normally in the hippocampus, studies of epilepsy have distinguished between patients with hippocampal lesions and those with lesions that do not affect the hippocampus. Subjects with temporal lobe epilepsy exhibited increased EAAT2 immunoreactivity in the CA1 and CA2 regions of the hippocampus compared with controls and showed a similar staining pattern. In contrast, subjects with epilepsy and hippocampal sclerosis exhibited decreased EAAT2 expression in all regions of the hippocampus compared with subjects without hippocampal sclerosis. RNA expression in the group without hippocampal sclerosis was significantly increased in CA3, while expression in the subjects with hippocampal sclerosis was significantly decreased in CA3, CA4 and the polymorphic layer. RNA expression was strong in neurons and weaker in glial cells. 99 A recent follow-up study found that patients with epilepsy, especially those without hippocampal sclerosis, were more likely to exhibit expression of the intron 7-retained and exon 9-skipped transcripts in the neocortex but not in the hippocampus. Although these variants were detected in normal controls as well, they were detected in a greater percentage of the subjects with epilepsy. 100 Moreover, GLT1 knockout mice die from epileptic seizures after 4-8 weeks, indicating that GLT1 dysfunction may be involved in the pathophysiology of epilepsy. 101 In addition, GLT1 expression and glutamate transport are decreased in a mouse model of tuberous sclerosis epilepsy, a disease involving seizures and mental retardation. 102 In a seizuresusceptible mouse strain, GLT1 mRNA and protein were downregulated in the parietal cortex, whereas in the hippocampus there was a decrease in mRNA expression without a corresponding decrease in the protein level. 103 This observation was corroborated in another study of genetically epilepsy-prone animals showing decreased GLT1 RNA expression in the cortex, striatum, CA1 and the inferior colliculus, without a corresponding change in protein levels. 104 The changes in RNA expression that are not reflected at the protein level suggest that post-transcriptional regulation of GLT1 may differ between seizuresusceptible and control animals.
Finally, in the normal human brain, EAAT2 is expressed at substantially lower levels in the fetal and neonatal periods, compared with expression at 1-2 years of age. 40 Seizures are most common in the neonatal period, 105 perhaps because relatively lower levels of EAAT2 limit the capacity for glutamate uptake during this critical developmental window.
Hypoxia/ischemia
Glutamate is released in ischemia and causes neurotoxicity due to reversed action of glutamate transporters. 106 Instead of taking up extracellular glutamate to protect neurons, the transporters release glutamate causing additional damage. A microdialysis study that measured glutamate levels in CA1 of GLT1 knockout and wild-type mice also provided evidence that the role of GLT1 may change from neuroprotective to neurodegenerative during ischemia. The mutant mice had higher glutamate levels during 5 min of ischemia, while they had lower glutamate levels toward the end of 20 min of ischemia. These observations suggest that GLT1 takes up glutamate in the early phase of ischemia but releases glutamate and causes neuronal death when the period of ischemia is elongated. 107 Furthermore, focal cerebral ischemia in rats induced by middle cerebral artery occlusion led to a decrease in GLT1 mRNA and protein expression EAAT2 regulation and splicing TL Lauriat and LA McInnes in the cerebral cortex. 108 Conversely, knocking down GLT1 expression with antisense oligodeoxynucleotides exacerbated ischemia induced by middle cerebral artery occlusion. 109 Changes in GLT1 expression following hypoxic preconditioning are regionally specific, with an increase in the cortex and a decrease in the striatum. 110 In addition, GLT1b expression was induced in neurons of neonatal pigs that experienced hypoxia, whereas GLT1 levels were decreased in this model. 63 Another study also found GLT1 expression in neurons in response to hypoxia/ischemia in newborn piglets that corresponded to a decrease in expression in astrocytes. 111 Once again, these studies fit with the theme of aberrant neuronal expression of GLT1 in pathological conditions.
Huntington's disease A postmortem study of striatal tissue from subjects with Huntington's disease found that reduced EAAT2 mRNA was correlated with disease severity. 112 Transgenic mice expressing a mutant huntingtin gene show reduced GLT1 mRNA and protein expression but no difference in expression of other glutamate transporters. 113 The decreased mRNA expression was apparent at six weeks and became more pronounced as the animals aged. However, glutamate levels measured by microdialysis were still within the normal range, suggesting that the loss of GLT1 is functionally compensated. This work confirmed the results of a similar study that showed that GLT1 mRNA is decreased to about 30% of normal levels in both the striatum and cortex of huntingtin mutant mice. 114 
Brain injury
Multiple studies have demonstrated altered GLT1 expression in various models of traumatic brain injury. Fluid percussion injury caused a sustained decrease in GLT1b in the ipsilateral cortex and a transient decrease in the hippocampus and thalamus with no effect on GLT1 or other glutamate transporters. 115 The selective decrease in GLT1b protein was observed in the cortex, hippocampus and thalamus, and the temporal course of the downregulation varied by region. Other studies have found decreased levels of GLT1 in response to controlled cortical impact injury. 116, 117 A postmortem study demonstrated that the extent of EAAT2 expression after traumatic brain injury varies with survival time and extent of the injury. EAAT2 levels were elevated substantially in cases with short survival times, probably in an attempt to compensate for increased extracellular glutamate levels. 118 Regulation of GLT1 by growth factors is particularly relevant to the issue of brain injury, since many of the molecules that regulate GLT1 expression are induced by injury. Injury-induced growth factors, including epidermal growth factor (EGF), transforming growth factor-a (TGF-a), fibroblast growth factor 2 (FGF2) combined with a mitogen-activated protein (MAP) kinase inhibitor and platelet-derived growth factor (PDGF), promote expression of GLT1 in cultured astrocytes. 119 However, GLT1 expression decreases in acute brain injury, even though the growth factors released should lead to increased expression. One possible explanation that has been proposed is ancillary effects of endothelins, which are also upregulated in response to injury and counteract the effects of growth factors. 120 
Glaucoma
Expression of the splice variant EAAT2c/GLT1c is induced in retinal ganglion cells in human glaucoma samples and in rat retina exposed to increased intraocular pressure. 121 In contrast, GLT1c is restricted to photoreceptors in the normal retina.
HIV-associated dementia
Cognitive impairment in the late stage of HIV infection is associated with altered glutamate uptake. Human primary astrocytes exposed to HIV-1, or its envelope glycoprotein gp120, exhibit a decrease in glutamate uptake that is accompanied by reduced EAAT2 RNA and protein expression. 122 Another group found that EAAT2 expression is increased during replication of the virus in macrophages, while glutamate uptake is decreased. 123 The reduced ability of astrocytes infected with the virus to take up glutamate may contribute to the neurological deficits that are linked to the disease. An HIV-inducible gene called astrocyte elevated gene 1 (AEG-1) inhibits EAAT2 promoter activity and may be part of the mechanism by which altered glutamate uptake contributes to a neurological phenotype in HIV patients. 124 Addiction Altered GLT1 expression has been reported in morphine addiction and withdrawal. 125, 126 Glutamate uptake was increased by 70% in hippocampal synaptosomes from rats that were chronically treated with morphine and then withdrawn. 126 There was a corresponding increase in GLT1 protein in the synaptosomes with no effect on the total GLT1 protein content. GLT1 expression was increased in hippocampal nerve terminals at the cell membrane from the morphine-treated rats, suggesting that GLT1 translocates to the membrane during morphine withdrawal. Cell surface expression increased in cultured neurons but not in astrocytes following morphine withdrawal. In another study, GLT1 mRNA was decreased in the striatum and thalamus of morphine-dependent rats and striatal GLT1 expression was increased in rats subjected to nalaxone-precipitated withdrawal. 127 No changes were detected in expression of GLAST, indicating that the effects were specific to GLT1. In addition, directly injecting GLT1 into the nucleus accumbens attenuated conditioned place preference to morphine and methamphetamine, 128 whereas injection of GLT1 into the locus coeruleus inhibited somatic signs of morphine withdrawal. 129 The compound (R)-(À)-methyl-1-nicotinoyl-2-pyrazoline (MS-153) protects the brain against injury and acts by EAAT2 regulation and splicing TL Lauriat and LA McInnes accelerating glutamate uptake via GLT1. 130 MS-153 reduced the development of morphine tolerance and physical dependence in mice. 131 MS-153 also attenuated conditioned place preference to morphine, methamphetamine and cocaine, but had no effect on acute locomotor responses to these drugs. 132 Thus, this compound appears to have a selective effect on the conditioned rewarding properties of the drugs. Riluzole is a modulator of glutamatergic transmission and is approved for the treatment of ALS, a condition in which EAAT2 is dysregulated. This compound also blocks conditioned place preference to morphine and amphetamine, suggesting that it could be explored as a therapeutic mechanism for addiction. 133 
Future directions in EAAT2 research
The complexity of EAAT2 regulation at both the transcript and protein levels suggests many additional areas of research. As mentioned earlier, discovery and characterization of possible alternative EAAT2 promoters and examination of promoterspecific chromatin modification is a critical area of inquiry. Allele-specific expression assays should also be conducted to test for differential expression of the various transcripts and provide markers for disease association studies. EAAT2 contains a coding polymorphism with a high enough minor allele frequency to make it suitable for this type of assay. In addition, with preliminary evidence that EAAT2 is regulated in an activity-dependent manner, electrophysiological studies should be conducted to determine whether expression of certain splice variants is induced in response to LTP or other types of stimulation. Likewise, additional work is necessary to identify unique targeting motifs in the 3 0 -UTR and to identify regulatory molecules that bind to the 3 0 -UTR. For example, putative translational effects of microRNAs that are predicted computationally to bind to EAAT2 should be followed up experimentally using reporter assays. Exploratory electrophoretic mobility shift assays and/or RNase protection assays could be used to determine whether RNA-binding proteins are in fact regulating the various 3 0 -UTRs. Although the 3 0 -UTRs do not appear to contain any known targeting motifs using current bioinformatic prediction programs, such sequences are likely to exhibit the kind of complexity observed to be characteristic of transcription factor binding sites so the utility of such programs may be limited for now. Regarding the aberrant splice forms that have been detected in brain, there is evidence that at least one of these variants has a dominant-negative effect on wild-type EAAT2 expression. 42 Therefore, although there may be no relationship between these transcripts and disease, it is still worth determining whether they are important for the normal regulation of EAAT2 expression, possibly under specific regional or physiological conditions.
There are also areas for further study at the protein level. Questions regarding the cellular and subcellular localization of the various protein isoforms have still not been resolved due to concerns about antibody specificity and variations in immunohistochemical techniques. A thorough exploration of possible posttranslational modifications of EAAT2 coding variants may be required in order to develop reliable antibodies that are suitable for immunohistochemistry. Such efforts may clarify some of the confusion about previous localization studies and the efficacy of current antibodies, especially if hypotheses that specific isoforms undergo regulated cleavage prove to be correct. Although several groups have identified proteins that interact with EAAT2, a comprehensive attempt to find EAAT2 binding partners has not been launched and few efforts have been made to identify proteins that interact with the unique regions of EAAT2b and EAAT2c. One should also remember that multiple regions of highly conserved sequence in the penultimate intron and the 3 0 -UTR of the major isoform suggest that additional EAAT2 exons may yet be identified and characterized.
Finally, additional studies are warranted to understand better the mechanisms by which EAAT2 is dysregulated both in human tissue and in animal models of disease states. ALS is clearly associated with a loss of EAAT2 protein in some, but not all, sporadic cases. For both ALS and AD, studies have shown decreased protein levels without a decrease in transcript levels, suggesting that dysregulation occurs post-transcriptionally. Evidence from animal models and human tissue studies also strongly supports a role for EAAT2 dysregulation in mood and anxiety disorders, suggesting that modulation of EAAT2 expression might be a productive therapeutic strategy. To this end, it would be helpful to understand whether changes in the expression of GLT1 induced by antipsychotic drugs correlate with symptom improvement versus the presence of particular side effects in animal models of schizophrenia. Finally, a recent report by the Autism Genome Project Consortium identified a new linkage peak for autism in the region of chromosome 11 where the gene for EAAT2 is located. 134 Given the disturbances of glutamatergic transmission in autism, the group has proposed that EAAT2 might be explored as a positional candidate for autism.
